December 2024 | Report Format: Electronic (PDF)
Cancer Registry Software Market Growth & Trends
The global cancer registry software market size is expected to reach USD 172.4 million by 2030, registering a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing incidence of cancer is expected to aid growth over the forecast period. Currently, cancer is the second leading cause of death globally, and according to WHO, around 70% of the deaths occur in low- and middle-income countries.
Moreover, rising adoption of Electronic Health Records (EHRs) in developed countries and increasing need for cancer registries for post-marketing surveillance are among the factors further anticipated to boost the demand for cancer registry software in the coming years. Market players are constantly involved in software updation in an attempt to minimize security risks and provide efficient software, thereby increasing market visibility and adoption. For instance, in April 2018, Elekta invested in PalabraApps LLC to improve its MOSAIQ Oncology Information System software.
Increasing number of clinical trials being conducted by major pharmaceutical and biotechnological companies is expected to drive the market over the forecast period. Cancer registry data helps in tracking patients for clinical trials. Moreover, the affected locations for any specific type of cancer can be identified by using this software. Major pharmaceutical companies are increasingly preferring cancer registry software owing to less requirement of internal staff, increased cost-effectiveness, and efficient management of resources, which is further widening the scope for growth.
Request a free sample copy or view report summary:
Cancer Registry Software Market Report
Cancer Registry Software Market Report Highlights
- Standalone software dominated the market and accounted for a share of 80.8% in 2023 attributed to its advanced features and easy-to-use tools.
- On the basis of deployment model, on-premise model segment dominated the market and accounted for a share of 59.8% in 2023.
- On the basis of components, the commercial segment dominated the market and accounted for a share of 75.0% in 2023 owing to its advantage of data safety as compared to the public database.
- The government & third-party segment dominated the market and accounted for a share of 27.2% in 2023.
- North America cancer registry software market accounted for the largest revenue share of 44.0% in 2023, owing to the presence of developed infrastructure.
- The Asia Pacific is expected to grow at the fastest CAGR of 14.8% over the forecast period, owing to increasing government initiatives in this region.
Cancer Registry Software Market Segmentation
Grand View Research has segmented the cancer registry software market on the basis of on software, deployment model, component, end-use, and region:
Cancer Registry Software Software Outlook (Revenue, USD Million, 2018–2030)
- Standalone
- Integrated
Cancer Registry Software Deployment Model Outlook (Revenue, USD Million, 2018–2030)
- On-premise
- Cloud Based
Cancer Registry Software Component Outlook (Revenue, USD Million, 2018–2030)
- Commercial
- Public
Cancer Registry Software End-use Outlook (Revenue, USD Million, 2018–2030)
- Government & Third Party
- Private Payers
- Hospital & Medical Practice
- Pharma Biotech & Medical Device Companies
- Research Institutes
Cancer Registry Software Regional Outlook (Revenue, USD Million, 2018–2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
List of Key Players in the Cancer Registry Software Market
- Elekta
- Oracle
- ONCO, Inc.
- IBM
- MCKESSON CORPORATION
- Conduent, Inc.
- Ordinate Corporation
- Volpara Health Limited
- Health Catalyst
- Rocky Mountain Cancer Data Systems (RMCDS) (University of Utah Health)
